Company intelligence / Profile preview

Walden Life Sciences

Cambridge, Massachusetts, United Stateswaldenu.edu ↗

Ownership: Private
Development stage: Other

Overview

WAL0921, an anti-suPAR monoclonal antibody, completed Phase 1+ in healthy subjects with proof-of-biology and good tolerability. A Phase 2 basket study in rare glomerular kidney diseases is ongoing. WAL0623, a small molecule dynamin stabilizer, has completed IND-enabling studies and will enter first-in-human trials in 2025

Therapeutic areas: Nephrology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Walden Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Walden Life Sciences.

Explore the full profile